MedTrace Logo

Identification of Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer

NCT04060537 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2019-08-19

No results posted yet for this study

Summary

This research study aims to investigate changes inside kidney cancers (also known as Renal Cell Carcinoma or RCC), and in normal kidney surrounding the tumour, when patients are treated with systemic therapy.

Samples, radiological images and data from a previous trial (NeoSUN) will be analysed and/or reanalysed, in accordance with the consent of NeoSUN participants.

Conditions

  • Carcinoma, Renal Cell

Interventions

OTHER

Laboratory analysis of samples

RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues

OTHER

Application of machine learning

Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.

Sponsors & Collaborators

  • CCTU- Cancer Theme

    lead OTHER

Principal Investigators

  • Sarah Welsh · Cambridge University Hospitals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2022-01-31
Completion
2022-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060537 on ClinicalTrials.gov